I. Introduction -
No pharmaceutical antitrust decision has had more impact than the Supreme Court’s 2013 decision in Federal Trade Commission v. Actavis, a decision which officially defined the term “reverse payment...more
10/11/2023
/ Abbreviated New Drug Application (ANDA) ,
Anti-Competitive ,
Antitrust Litigation ,
AstraZeneca ,
Causation ,
Food and Drug Administration (FDA) ,
FTC v Actavis ,
Generic Drugs ,
Hatch-Waxman ,
Motion to Dismiss ,
Orange Book ,
Pharmaceutical Industry ,
Popular ,
RanBaxy ,
Reverse Payment Settlement Agreements ,
SCOTUS ,
Settlement
Introduction Pharmacy benefit managers (PBMs) are the healthcare system players most patients have never heard of. Yet, PBMs represent a multibillion-dollar industry that touches the majority of Americans’ lives. Known as...more
Six months after the Department of Justice (“DOJ”), United States Patent and Trademark Office (“USPTO”), and the National Institute of Standards and Technology (“NIST”) issued a Draft Policy Statement on Licensing...more
In the world of technology, Standard Setting Organizations (“SSOs”) play a crucial role in helping to facilitate innovation. They do so by creating industry standards that ensure quality and promote and enable the development...more
A federal district court recently dismissed a lawsuit against AbbVie and biosimilar manufacturers of adalimumab involving a novel antitrust claim against the Humira patent estate. Attorneys with Haug Partners LLP take an...more
7/20/2020
/ AbbVie ,
Amgen ,
Anticompetitive Behavior ,
Antitrust Litigation ,
Antitrust Violations ,
Biosimilars ,
BPCIA ,
Defense Strategies ,
Dismissals ,
Drug Pricing ,
EU ,
Federal Trade Commission (FTC) ,
Foreign Patent Applications ,
Indirect Purchasers ,
Litigation Strategies ,
Noerr-Pennington Doctrine ,
Orange Book ,
Patent Dance ,
Patent Portfolios ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Popular ,
Product Exclusivity
On July 8, 2020, Judge Alison Burroughs granted-in-part Defendants Shire and Actavis’s motion to decertify a direct purchaser plaintiff class in an alleged reverse payment antitrust case pending in the Federal District Court...more
7/13/2020
/ Antitrust Violations ,
Chapter 11 ,
Class Action ,
Class Certification ,
Class Representatives ,
Commercial Bankruptcy ,
Conflicts of Interest ,
Decertification ,
Defense Strategies ,
Direct Purchasers ,
Disqualified Persons ,
Pharmaceutical Industry ,
Popular ,
Wholesale